BioConnect AG advised financing round for 20/10 Perfect Vision AG
Frankfurt/Main, October 2007 - BioConnect AG acted as exclusive financial advisor to Heidelberg – based medical technology company 20/10 Perfect Vision AG (“20/10 PerfectVision”) in a € 13.5 million (USD 19.2 million) financing round.
NBGI Ventures (London) acted as lead investor and IBG Beteiligungsgesellschaft mbH, Sachsen - Anhalt (Magdeburg) as co-investor, joining the existing financing syndicate that includes, among others, Innoven Partennaires (Paris) and Entrepreneurs Fund (Amsterdam).
The funding proceeds will enable the company to accelerate the market penetration of its FEMTEC femtosecond laser workstation unit with its novel applications for ophthalmic surgery recently introduced to the international markets. The system offers eye surgeons a broad variety of innovative procedures including refractive laser surgery applications. The funding will further accelerate the development of totally new procedures in ophthalmology.
This transaction further enhances BioConnect’s track record in the medical technology sector and represents the second financing deal in 2007, following the successful fundraising of cardiac imaging company BMDSys GmbH earlier this year.
BioConnect, a member of Corporate Finance Partners Group based in Frankfurt/ Germany, acted as adviser to 20/10 Perfect Vision AG in this financing round.
«back
NBGI Ventures (London) acted as lead investor and IBG Beteiligungsgesellschaft mbH, Sachsen - Anhalt (Magdeburg) as co-investor, joining the existing financing syndicate that includes, among others, Innoven Partennaires (Paris) and Entrepreneurs Fund (Amsterdam).
The funding proceeds will enable the company to accelerate the market penetration of its FEMTEC femtosecond laser workstation unit with its novel applications for ophthalmic surgery recently introduced to the international markets. The system offers eye surgeons a broad variety of innovative procedures including refractive laser surgery applications. The funding will further accelerate the development of totally new procedures in ophthalmology.
This transaction further enhances BioConnect’s track record in the medical technology sector and represents the second financing deal in 2007, following the successful fundraising of cardiac imaging company BMDSys GmbH earlier this year.
BioConnect, a member of Corporate Finance Partners Group based in Frankfurt/ Germany, acted as adviser to 20/10 Perfect Vision AG in this financing round.
